Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-chloro-5-(1h-tetrazol-5-yl)-n(sup 4)-2-thenylsulfanilamide
2. 5-(4-chloro-5-sulfamyl-2-thienylaminophenyl)tetrazole
3. Azosemid
4. Benzenesulfonamide, 2-chloro-5-(1h-tetrazol-5-yl)-4-((2-thienylmethyl)amino)-
5. Bm 02.001
6. Ple 1053
1. 27589-33-9
2. Azosemid
3. Diart
4. Azosemida
5. Azosemidum
6. Luret
7. 2-chloro-5-(2h-tetrazol-5-yl)-4-((thiophen-2-ylmethyl)amino)benzenesulfonamide
8. Ple 1053
9. 2-chloro-5-(1h-tetrazol-5-yl)-n(sup 4)-2-thenylsulfanilamide
10. Mr40vt1l8z
11. 2-chloro-5-(2h-tetrazol-5-yl)-4-(thiophen-2-ylmethylamino)benzenesulfonamide
12. Chebi:31248
13. Sulfanilamide, 2-chloro-5-(1h-tetrazol-5-yl)-n(sup 4)-2-thenyl-
14. Benzenesulfonamide, 2-chloro-5-(1h-tetrazol-5-yl)-4-((2-thienylmethyl)amino)-
15. 5-(4'-chloro-5'-sulfamoyl-2'-thenylaminophenyl)tetrazole
16. Ncgc00181340-01
17. Dsstox_cid_26910
18. Dsstox_rid_82008
19. Dsstox_gsid_46910
20. 2-chloro-5-(1h-tetrazol-5-yl)-n4-2-thenylsulfanilamide
21. Azosemidum [inn-latin]
22. Azosemida [inn-spanish]
23. 2-chloro-5-(1h-tetrazol-5-yl)-4-[(thiophen-2-ylmethyl)amino]benzenesulfonamide
24. Azosemide [usan:inn:jan]
25. Cas-27589-33-9
26. Einecs 248-549-7
27. Sk-110
28. Unii-mr40vt1l8z
29. Brn 1178491
30. Diart (tn)
31. 5-(4'-chloro-5'-sulfamoyl-2'-thenylaminophenyl)-tetrazole
32. Azosemide [inn]
33. Azosemide [jan]
34. Azosemide [mi]
35. Azosemide [usan]
36. Azosemide [mart.]
37. Azosemide [who-dd]
38. Schembl48976
39. Azosemide (jp17/usan/inn)
40. Chembl1097235
41. Dtxsid7046910
42. Amy7468
43. Ex-a1266
44. Zinc5843546
45. Tox21_112799
46. Ac-096
47. Mfcd30541344
48. Sk 110
49. Akos015961824
50. Tox21_112799_1
51. Db08961
52. Benzenesulfonamide, 2-chloro-5-(2h-tetrazol-5-yl)-4-[(2-thienylmethyl)amino]-
53. Ncgc00181340-02
54. As-12235
55. Db-047249
56. Hy-107321
57. Cs-0028137
58. Ft-0602886
59. C74435
60. D01323
61. 589a339
62. A913169
63. Q4832859
64. 5-(4-chloro-5-sulfamoyl-2-thenylaminophenyl)-tetrazole
65. 2-chloro-5-(1h-tetrazol-5-yl)-n(4)-2-thenylsulfanilamide
66. 2-chloro-5-(1h-tetrazol-5-yl)-4-(thiophen-2-ylmethylamino)benzenesulfonamide
67. 2-chloro-5-(2h-1,2,3,4-tetrazol-5-yl)-4-[(thiophen-2-ylmethyl)amino]benzene-1-sulfonamide
| Molecular Weight | 370.8 g/mol |
|---|---|
| Molecular Formula | C12H11ClN6O2S2 |
| XLogP3 | 1.5 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | 370.0073437 g/mol |
| Monoisotopic Mass | 370.0073437 g/mol |
| Topological Polar Surface Area | 163 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 504 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Diuretic affects upon oral administration match those of furosemide. However, upon intravenous administration azosemide displays 5.5 to 8 times greater effect.
Diuretics
Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)
Absorption
Peak plasma concentrations are achieved in 3-4 hours when azosemide is administered to healthy humans in a fasting state. There is an absorption lag time of approximately 1 hour. Oral bioavailability estimated to be 20.4%
Route of Elimination
Total body clearance 112ml/min. Renal clearance 41.6ml/min. Actively secreted in the renal proximal tubule of humans. This may or may not involve a nonspecific organic acid secretory pathway. There is thus a potential for disease states and other organic acids such as NSAIDs which affect the organic acid transport pathway to affect the efficacy of azosemide.
Volume of Distribution
Poor affinity for human tissue. Small apparent post-pseudodistribution Vd of 0.262 l/kg.
Considerable first pass metabolism which makes parentral administration more effective than oral administration. Eleven metabolites of azosemide were found in rats, but only azosemide and its glucuronide were detected in humans.
Terminal half life 2-3 hours.
Exact mechanism of action is unclear. However, it acts primarily on the loop of Henle, in both the medullary and cortical segments of the thick ascending limb.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Market Place
ABOUT THIS PAGE
A Azosemide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Azosemide, including repackagers and relabelers. The FDA regulates Azosemide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Azosemide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Azosemide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Azosemide supplier is an individual or a company that provides Azosemide active pharmaceutical ingredient (API) or Azosemide finished formulations upon request. The Azosemide suppliers may include Azosemide API manufacturers, exporters, distributors and traders.
click here to find a list of Azosemide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Azosemide Drug Master File in Japan (Azosemide JDMF) empowers Azosemide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Azosemide JDMF during the approval evaluation for pharmaceutical products. At the time of Azosemide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Azosemide suppliers with JDMF on PharmaCompass.
Azosemide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Azosemide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Azosemide GMP manufacturer or Azosemide GMP API supplier for your needs.
A Azosemide CoA (Certificate of Analysis) is a formal document that attests to Azosemide's compliance with Azosemide specifications and serves as a tool for batch-level quality control.
Azosemide CoA mostly includes findings from lab analyses of a specific batch. For each Azosemide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Azosemide may be tested according to a variety of international standards, such as European Pharmacopoeia (Azosemide EP), Azosemide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Azosemide USP).
LOOKING FOR A SUPPLIER?
